Literature DB >> 15592725

The neuroprotective role of inflammation in nervous system injuries.

Jorge Correale1, Andrés Villa.   

Abstract

The contribution of inflammation to the pathogenesis of several nervous system disorders has long been established. Other observations, however, indicate that both inflammatory cells and mediators may also have beneficial functions, assisting in repair and recovery processes. There is compelling evidence to indicate that in the injured nervous system, as in other tissues, macrophages are needed at an early stage after injury in order for healing to take place. Likewise, activated T cells of a particular specificity can reduce the spread of damage. This neuroprotective effect of T cells may be caused, at least in part, by the production of neurotrophic factors such as neurotrophin-3 or brain-derived neurotrophic factor. Interestingly, recent findings indicate that immune cells are able to produce a variety of neurotrophic factors which promote neuronal survival and may also mediate anti-inflammatory effects. Numerous cytokines are induced after nervous system injuries. Some cytokines, such as TNF-alpha, IL-1 and IFN-gamma, are well known for their promotion of inflammatory responses. However, these cytokines also have immunosuppressive functions and their subsequent expression also assists in repair or recovery processes, suggesting a dual role for some pro-inflammatory cytokines. This should be clarified, as it may be crucial in the design of therapeutic strategies to target specific cytokine(s). Finally, there is a growing body of evidence to show that autoreactive IgM antibodies may constitute an endogenous system of tissue repair, and therefore prove of value as a therapeutic strategy. Available evidence would appear to indicate that the inflammatory response observed in several neurological conditions is more complex than previously thought. Therefore, the design of more effective therapies depends on a clear delineation of the beneficial and detrimental effects of inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592725     DOI: 10.1007/s00415-004-0649-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  155 in total

1.  Rat and human Schwann cells in vitro can synthesize and express MHC molecules.

Authors:  P J Armati; J D Pollard; P Gatenby
Journal:  Muscle Nerve       Date:  1990-02       Impact factor: 3.217

2.  Wallerian degeneration in the peripheral nervous system: participation of both Schwann cells and macrophages in myelin degradation.

Authors:  G Stoll; J W Griffin; C Y Li; B D Trapp
Journal:  J Neurocytol       Date:  1989-10

3.  Growth factor treatment of demyelinating disease: at last, a leap into the light.

Authors:  Richard M Ransohoff; Charles L Howe; Moses Rodriguez
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

4.  Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors.

Authors:  M Besser; R Wank
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

5.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

6.  BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

Authors:  Christine Stadelmann; Martin Kerschensteiner; Thomas Misgeld; Wolfgang Brück; Reinhard Hohlfeld; Hans Lassmann
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

7.  The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination.

Authors:  Tara Karnezis; Wim Mandemakers; Jonathan L McQualter; Binhai Zheng; Peggy P Ho; Kelly A Jordan; Belinda M Murray; Ben Barres; Marc Tessier-Lavigne; Claude C A Bernard
Journal:  Nat Neurosci       Date:  2004-06-06       Impact factor: 24.884

8.  Interleukin-1 alpha, but not interleukin-1 beta, is a co-mitogen for neonatal rat Schwann cells in vitro and acts via interleukin-1 receptors.

Authors:  R P Lisak; B Bealmear; S Ragheb
Journal:  J Neuroimmunol       Date:  1994-12       Impact factor: 3.478

9.  Hyperinducibility of Ia antigen on astrocytes correlates with strain-specific susceptibility to experimental autoimmune encephalomyelitis.

Authors:  P T Massa; V ter Meulen; A Fontana
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

10.  Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: implications for protective autoimmunity.

Authors:  Rina Barouch; Michal Schwartz
Journal:  FASEB J       Date:  2002-06-21       Impact factor: 5.191

View more
  48 in total

1.  Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury.

Authors:  Julie L Chan; Thomas M Reeves; Linda L Phillips
Journal:  Exp Neurol       Date:  2014-08-21       Impact factor: 5.330

Review 2.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

3.  Comparison of the effect of minocycline and simvastatin on functional recovery and gene expression in a rat traumatic brain injury model.

Authors:  Cole Vonder Haar; Gail D Anderson; Brandy E Elmore; Lynn H Moore; Amanda M Wright; Eric D Kantor; Fred M Farin; Theo K Bammler; James W MacDonald; Michael R Hoane
Journal:  J Neurotrauma       Date:  2014-01-20       Impact factor: 5.269

Review 4.  Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury.

Authors:  Jenna M Ziebell; Maria Cristina Morganti-Kossmann
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

Review 5.  Modulating the Immune Response Towards a Neuroregenerative Peri-injury Milieu After Cerebral Hemorrhage.

Authors:  Damon Klebe; Devin McBride; Jerry J Flores; John H Zhang; Jiping Tang
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-07       Impact factor: 4.147

6.  Severe traumatic head injury affects systemic cytokine expression.

Authors:  Damien J LaPar; Laura H Rosenberger; Dustin M Walters; Traci L Hedrick; Brian R Swenson; Jeffrey S Young; Lesly A Dossett; Addison K May; Robert G Sawyer
Journal:  J Am Coll Surg       Date:  2012-02-17       Impact factor: 6.113

7.  IFN-β alters neurotrophic factor expression in T cells isolated from multiple sclerosis patients - implication of novel neurotensin/NTSR1 pathway in neuroprotection.

Authors:  John Soltys; Julia Knight; Eugene Scharf; David Pitt; Yang Mao-Draayer
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

8.  The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFalpha-induced sickness behavior.

Authors:  Karine Palin; Rose-Marie Bluthé; Robert H McCusker; Thierry Levade; Françoise Moos; Robert Dantzer; Keith W Kelley
Journal:  Psychopharmacology (Berl)       Date:  2008-09-30       Impact factor: 4.530

9.  Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway.

Authors:  Aida Maddahi; Lars Edvinsson
Journal:  J Neuroinflammation       Date:  2010-02-26       Impact factor: 8.322

10.  NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats.

Authors:  Hans H Wei; Xi-Chun M Lu; Deborah A Shear; Anu Waghray; Changping Yao; Frank C Tortella; Jitendra R Dave
Journal:  J Neuroinflammation       Date:  2009-08-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.